Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-53718678 for RSV upper respiratory tract infection in hematopoietic stem cell transplant recipients
NL-OMON55100Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing JNJ-53718678 with Placebo (2 arms). Primary endpoint: Proportion of participants who develop RSV lower respiratory tract infection. Started Oct 2019; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON55100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55100.